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Purpose: The aim of this study was to evaluate the improvement of osteogenic potential of biphasic calcium phosphate (BCP) 
bone substitute coated with synthetic cell-binding peptide sequences in a standardized rabbit sinus model.
Methods: Standardized 6-mm diameter defects were created bilaterally on the maxillary sinus of ten male New Zealand white 
rabbits, receiving BCP bone substitute coated with synthetic cell binding peptide sequences on one side (experimental group) 
and BCP bone substitute without coating (control group) on the other side. Histologic and histomorphometric analysis of bone 
formation was carried out after a healing period of 4 or 8 weeks.
Results: Histological analysis revealed signs of new bone formation in both experimental groups (4- and 8-week healing 
groups) with a statistically significant increase in bone formation in the 4-week healing group compared to the control group. 
However, no statistically significant difference in bone formation was found between the 8-week healing group and the con-
trol group.
Conclusions: This study found that BCP bone substitute coated with synthetic cell-binding peptide sequences enhanced os-
teoinductive potential in a standardized rabbit sinus model and its effectiveness was greater in the 4-week healing group than 
in the 8-week healing group.
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INTRODUCTION
Various bone substitutes have been used for sinus floor ele-
vation procedures. Autologous bone is considered the gold 
standard [1-3]. However, the autologous bone transplanted 
may have an inconsistent rate of mineralization, due to the 
ratio of cortical to cancellous bone, and given that it also re-
quires an additional donor-site surgery, it may not thus al-
ways be the material of choice for sinus floor elevation [3].
Recently, biphasic calcium phosphate (BCP) bone substitute 
has been investigated and used in sinus floor elevation pro-
cedures with favorable treatment outcomes [4-6]. BCP is a 
proven safe and biocompatible synthetic bone substitute that 
is widely used in orthopedic, maxillofacial, and periodontal 
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surgery [7,8]. BCP is known to have mainly osteoconductive 
properties [8]. Therefore, there have been various efforts to 
improve the osteogenic potential of this BCP with growth 
factor, recombinant human bone morphogenetic protein 
(rhBMP)-2 [9,10]. Previous studies using BCP treated with rh-
BMP-2 on rat calvarial defects have shown improved osteo-
inductive potentials when compared with untreated BCP. 
However, considering side effects such as the swelling of soft 
tissues and ectopic bone and cyst-like bone void formation, 
rhBMP-2 should not be applied to all periodontal defects or 
used in sinus floor elevation [11-13].
Biologically active peptides have been bound to the surface 
of inorganic bone substitutes to improve the performance of 
biomaterial with limited osteoinductive potentials [14-16]. 
PepGen (P-15) is a Food and Drug Administration approved 
tissue engineered product that contains a synthetic 15 amino 
acid sequence (766GTPGPQGIAGQRGVV780) of the α1-chain 
in Type I collagen, which is uniquely involved in binding of 
cells such as fibroblasts or osteoblasts [17-19]. In previous 
studies, it was shown that there was an increase in the attach-
ment and viability of cells bound to an inorganic bone sub-
stitute with P-15 when compared with those without P-15 
[20,21]. Favorable results in animal and clinical studies were 
also reported when using inorganic bone substitute with P-15 
[14, 22]. However, binding of this biologically active peptide 
to BCP has not yet been attempted or investigated thorough-
ly. Therefore, the purpose of this study was to evaluate the 
improvement of osteogenic potential of BCP coated with 
synthetic peptide (amino acid sequence of 766GTPGPQ-
GIAGQRGVV780).
MATERIALS AND METHODS 
Study design
Standardized, bilateral, circular, transosseous, 6-mm diam-
eter defects were created on the maxillary sinuses of the sub-
jects. The bone graft material used in this study was BCP bone 
substitute, Osteon (Dentium Co., Seoul, Korea), which consists 
of 70% hydroxyapatite and 30% β-TCP (Table 1).
Preparation of oligopeptide-coated BCP
A peptide sequence of 766GTPGPQGIAGQRGVV780 was 
obtained from the manufacturer (Sigma-Aldrich Japan, Ishi-
kari, Japan). Surface coating was then performed to combine 
hydroxyapatite, a constituent of BCP (Osteon, Dentium Co.), 
with the peptide. At first, the hydroxyl group of hydroxya-
pitite was linked with 3-aminopropyltriethoxysilane (Sigma-
Aldrich Co., St. Louis, MO, USA), then linked with N-succin-
imidyl 3-maleimidopropionate (Sigma-Aldrich Co.), followed 
by a linkage with the peptide sequence. The BCP was soaked 
in the peptide solution and stored at -70°C in a deep-freezer. 
To sublimate the liquid phase and avoid denaturalizing the 
peptide, the frozen solution was then placed for a day in a vial 
in a lyophilizer (Ilshin Lab., Seoul, Korea). The lyophilization 
setting was put at -45°C to -50°C with a high vacuum of 7 to 
10 mTorr, and the dried granules were kept in a freezer until 
use. The peptide-coated BCP was sterilized with ethylene ox-
ide (EO) gas in a gas sterilizer (Steri-Vac 400B, 3M, St. Paul, 
MN, USA) at 29°C for 5 hours; this is considered the ideal 
sterilization protocol without hampering osteoinductive ac-
tivity [23].
Surgical procedure
Ten male New Zealand white rabbits (body weight, 2.5 to 3.0 
kg) were used for this study. The window position on the 
maxillary sinus of rabbits was determined according to the 
instructions of Asai et al. [24]: 20 mm anterior to the naso-
frontal suture line and 10 mm lateral to the midline.
Prior to all surgical procedures, the animals were anesthe-
tized with a cocktail of ketamine hydrochloride (Ketalar, Yu-
han, Seoul, Korea) and xylazine (Rumpun, Bayer Korea Ltd., 
Seoul, Korea) via an intramuscular injection. The surgical site 
was then shaved and sterilized with a povidon-iodine solu-
tion, followed by local anesthesia of 2% lidocaine with 
1:100,000 epinephrine. After making a straight incision along 
the sagittal midline on the nasal bone, a full-thickness flap 
was reflected, exposing the calvarial bone. A standardized, 
circular, bilateral, transosseous window was created on the 
maxillary sinus using 6-mm-diameter trephine bur while be-
ing irrigated copiously with saline. A pin was also inserted at 
the mid-point between the two windows to indicate the ref-
erence point for micro-computed tomography (CT) analysis. 
Following removal of the trephined calvarial disk, the experi-
mental and control treatments of grafting material were ap-
plied to the windows accordingly (Table 1). The periosteum 
was then repositioned over the windows and all surgical sites 
were sutured with 4-0 Monosyn (Glyconate absorbable 
monofilament, B-Braun, Aesculap, Center Valley, PA, USA). 
The animals were euthanized 4 or 8 weeks after the surgery.
Radiographic analysis: micro-CT
The harvested block sections, including the augmented si-
Table 1. Study design.
Groups Materials Experimental period Defect number
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nus and the surrounding bone, were fixed in 10% buffered 
formalin for 10 days and scanned using micro-CT (SkyScan 
1076, SkyScan, Aartselaar, Belgium) at a resolution of 35 μm 
(100 kV and 100 μA). The area of interest was reconstructed 
with Ondemand 3D software (Cybermed, Seoul, Korea) and 
rendered visually in 3D. The CT volume was calculated from 
the percentage of window closure using an automated im-
age-analysis system (Image-Pro Plus, Media Cybernetics Inc., 
Silver Spring, MD, USA).
Histologic analysis 
After the micro-CT image was obtained, each of the sec-
tions was decalcified in 5% formic acid for 14 days and then 
embedded in paraffin. Serial 5-μm-thick sections were cut 
coronally along the center of the circular calvarial defects. 
The 2 central-most sections were selected and stained with 
hematoxylin and eosin (H&E) for light microscope examina-
tion (BX50, Olympus Co., Tokyo, Japan).
Histometric analysis 
An automated image-analysis system (Image-Pro Plus, Me-
dia Cybermetics Inc.) was used for computer-assisted histo-
metric analysis. Two parameters were measured: newly 
formed bone area (NB%) and remaining graft area (RG%). 
NB% was measured by calculating newly formed mineral-
ized bone in the window as a percentage of total augmented 
bone area, measured as all tissues within the boundary of the 
newly formed bone. RG% was measured by calculating the 
area of the remaining grafting materials as a percentage of 
the total augmented bone area.
Statistical analysis
Micro-CT data and histomorphometric measurement of 
the samples were used to calculate group mean±SD values. 
The Mann-Whitney U test was performed using SPSS ver. 
15.0 (SPSS Inc., Chicago, IL, USA) to compare differences be-
tween the control group and the experimental group, as well 
as differences between two experimental groups according 
to time of healing. A P-value less than 0.05 was considered 
statistically significant. 
RESULTS
Radiographic & histometric analysis
In the 4-week healing group, NB% was statistically signifi-
cantly greater in the experimental group than in the control 
group (P<0.05). RG% was less in the experimental group than 
in the control group. However, no statistically significant dif-
ference was found in the control and experimental groups’ 
RG% values. In the 8-week healing group, while CT volume 
was statistically significantly greater in the experimental 
group than in the control group (P<0.05), no statistical differ-
ence was found in NB%, despite its increased value (Table 2).
Histological findings 
Histological findings revealed that increased new bone 
formation was particularly evident in the experimental group 
(BCP coated with oligopeptide) when compared to that of the 
control group (BCP alone). Additionally, more osteoblasts and 
osteocytes in lacunae were identified in the experimental 
group (Figs. 1 and 2). In general, within the experimental 
group, more vascularization and the presence of newly 
formed blood vessels were identified in the 4-week healing 
Table 2. Measurements in standardized rabbit sinus model.
Point in time  Groups Materials New bone (%) Remaining graft (%) CT volume
4 weeks Control BCP 18.40±4.33 32.61±4.70 19.85±1.33
Experimental BCP coated with oligopeptide  28.13±6.02 29.23±11.97 29.57±4.68
8 weeks Control BCP  21.57±6.76 27.43±5.96 16.27±1.70
Experimental BCP coated with oligopeptide  30.53±5.36 26.51±6.17 24.53±1.55
Values are presented as mean±SD.
CT: computed tomography, BCP: biphasic calcium phosphate.
Figure 1. Histological findings of control group (biphasic calcium 
phosphate) at 4 weeks. (A) Area of interest (H&E, ×12.5), (B) defect 
margin area (H&E, ×50), (C) the Schneiderian membrane (H&E, 
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group. Immature woven bone, still undergoing the mineral-
ization process, was found to be dominant in the 4-week 
healing group relative to the 8-week healing group (Fig. 3).
In contrast, the Schneiderian membrane was slightly thick-
ened in the 8-week healing group. The shape of the graft 
material was also smoothened, which indicates the resorp-
tion of graft material particles (Fig. 4). In between graft mate-
rial particles, Haversian systems and interstitial lamella were 
observed, both of which are indicative of matured lamellar 
bone (Fig. 5).
DISCUSSION
There have been many attempts to increase the osteoin-
ductivity of bone graft materials by using a variety of growth 
factors. The use of BMPs, in particular, has shown favorable 
Figure 2. Histological findings of experimental group (biphasic cal-
cium phosphate coated with oligopeptides) at 4 weeks. (A) Area of 
interest (H&E, ×12.5), (B) defect margin area (H&E, ×50), (C) the 




Figure 4. Histological findings of experimental group (biphasic cal-
cium phosphate coated with oligopeptides) at 8 weeks. (A) Area of 
interest (H&E, ×12.5), (B) defect margin area (H&E, ×50), (C) the Sch-
neiderian membrane (H&E, ×50), and (D) middle area (H&E, ×50). 
The Schneiderian membrane was thicker than that of the 4-week 
healing group. Also, the shape of graft materials was smoothened, 
which indicates the resorption of graft material particles.
A
B C D
Figure 3. Histological findings of the Schneiderian membrane in 
experimental group (biphasic calcium phosphate coated with oligo-
peptides) at 4 weeks. The Schneiderian membrane (H&E, ×50). More 
vascularization (white asterisks) with newly formed blood vessels 
(arrows) were identified in the 4-week healing group. Bone matrix, 
including osteoblasts (arrowheads), was also observed.
Figure 5. Histological findings of middle area in experimental group 
(biphasic calcium phosphate coated with oligopeptides) at 8 weeks. 
Middle area (H&E, ×50). Haversian systems (arrowheads) and inter-
stitial lamella (black asterisks) were observed, both of which are in-
dicative of matured lamellar bone.
results in promoting bone formation [25] and has therefore 
been investigated to assess its effectiveness through various 
animal models [26]. However, the use of BMPs also appears 
to be difficult to handle due to their high molecular weight, 
the technical difficulties in binding them to bone graft parti-
cles, their relatively high cost, and the complexity of immu-
nologic responses [27,28]. Moreover, there is also the limiting 
factor of establishing an optimum therapeutic concentration 
of BMPs; since various unwanted side-effects have been re-
ported, such as ectopic bone formation, cyst-like bone void 
formation, and soft tissue swelling when supraphysiologic 
doses of BMPs were used [11,12].
Because of this unpredictability, receptor technologies, par-
ticularly the use of specific peptide sequences (oligopeptide) 
involved in binding to cells such as fibroblasts or osteoblasts, 
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have been posited as alternatives. Saito et al. [29] have report-
ed that 73 to 92 peptide combined with the porous a-TCP 
scaffold almost completely repaired a 20-mm long rabbit ra-
dial bone defect 12 weeks after implantation. Suzuki et al. [30] 
have also shown that alginate hydrogel linked with synthetic 
oligopeptiode derived from BMP-2 promoted ectopic bone 
formation. Among many peptide sequences, the use of P-15 
in particular, which includes synthetic 15 peptide sequence 
(766GTPGPQGIAGQRGVV780) of the α1-chain in Type I col-
lagen, has already shown favorable results in the treatment 
of periodontal defects and in sinus-lifting procedures [14,22]. 
Park et al. [14] have also reported that 15 amino acids corre-
sponding to the BMP I and II receptor-binding domains coat-
ed on granules of bovine bone mineral significantly accelerat-
ed new bone formation in a rabbit calvarial defect model. The 
use of this oligopeptide corresponding to the BMP receptor-
binding domains also proved effective in enhancing the bone 
regenerative capacity in a beagle dog’s 1-wall intrabony defect 
model [31].
To date, there have been many studies attempting to in-
crease the osteoinductive potential of BCP, one of the most 
widely used bone graft materials, by coating it with BMPs. 
However, the effects of binding a biologically active peptide 
to BCP to increase osteoinductive potential have not been 
investigated thoroughly. Therefore, the purpose of the pres-
ent study was to evaluate the improvement of osteogenic 
potential of BCP coated with synthetic peptide (amino acid 
sequence of 766GTPGPQGIAGQRGVV780).
In order to provide precisely the same conditions to the 
control and the experimental group and to minimize proce-
dural errors, the experiment conducted in the study used the 
standardized rabbit sinus model with the same window shape 
and size introduced by De Souza Nunes et al. [32]. According 
to Roberts and Breznak [33], the rabbit metabolic rate is known 
to be three to four times faster than that of the human. 
Therefore healing periods of 4 and 8 weeks were chosen 
based on the assumption that a 4-week and an 8-week heal-
ing period for rabbits would correspond to a 3- to 4-month 
and a 6- to 8-month healing period in humans, respectively. 
From histomorphometric analysis, it was found that in the 
4-week healing group, new bone formation was statistically 
significantly greater in the experimental group than the con-
trol group. This result is in accordance with previous studies 
[34-36], as it was thought that bone graft material coated with 
oligopeptide would promote cell adhesion and cell differen-
tiation, providing more favorable conditions for new bone 
formation. CT volume was also statistically significantly in-
creased in the experimental group than the control group, 
which also supports the idea that bone graft materials with 
oligopeptide coating have more osteoinductive potential. 
However, in the 8-week healing group, though both new 
bone formation and CT volume in the experimental group 
were greater than those of the control group, there was no 
statistically significant difference in bone formation or CT 
volume between the 4-week healing group and the 8-week 
healing group. 
Park et al. [14] also reported that oligopeptide domain-coat-
ed bovine bone mineral promoted new bone formation at 2 
and 4 weeks postsurgery. The results of the current study 
show the effect of oligopeptide on early bone formation is 
clearly evident in the 4-week healing group but not as nota-
ble in the 8-week healing group. Perhaps, then, it can be sug-
gested that oligopeptide coating may be more beneficial for 
bone regeneration in the early healing period. On the other 
hand, the current results may also be due to a high standard 
deviation resulting from a limited sample size. In this case, 
further studies with a greater sample size may help to better 
determine the effectiveness of oligopeptide coating accord-
ing to healing time. 
Within the experimental group, the 8-week healing group 
showed greater bone formation than did the 4-week healing 
group, which demonstrates that the process of bone forma-
tion continued to occur between the 4th and 8th weeks. For 
this reason, it may be beneficial to observe the bone forma-
tion process even after an 8-week period of time in order to 
accurately determine the effect of the oligopeptide coating 
on healing time. It is interesting to note that CT volume in 
the 8-week healing group was lower. One interpretation of 
this is that the replacement of biomaterial with newly formed 
bone does not necessarily occur at a 1:1 ratio, which is in agree-
ment with Frenken et al. [5]. In other words, less bone is pro-
duced in this case, compared to the volume of biomaterials 
resorbed.
In conclusion, this study found that BCP bone substitute 
coated with biologically active peptide sequences enhanced 
osteoinductive potential in a standardized rabbit sinus model 
and, within the limitations of this study, it can be assumed 
that oligopeptide coating is more beneficial for bone regen-
eration in the early healing period.
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